Merck


FDA Advisory Panel Votes In Favor Of Approval For Merck's Vorapaxar

FDA Advisory Panel Votes In Favor Of Approval For Merck's Vorapaxar

The FDA’s Cardiovascular and Renal Drugs Advisory Committee voted 10-1 in favor of approval for vorapaxar, Merck's novel thromb...

Jan 15 2014, 5:21pm CST

I4U news

Merck's Vorapaxar Gets Positive FDA Review

A few years ago a novel antiplatelet agent from Merck seemed all but dead. Vorapaxar, a thrombin receptor antagonist, was widel...

Jan 13 2014, 2:31pm CST

I4U news

Four Reasons Merck's R&D Restructuring May Not Save The Drug Giant (Or The Industry)

Last Friday, Wall Street Journal reporters Peter Loftus and Jonathan Rockoff broke the story that Merck is planning a dramatic...

Dec 29 2013, 11:26am CST

I4U news

Merck's Pursuit Of Weight-Loss Business Is Savvy, Not Stupid

I was surprised by the harsh reception that greeted Merck’s announcement today that it has launched a new weight management bus...

Dec 20 2013, 5:51pm CST